The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Gilles SallesDuring the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Gilles Salles, South Lyon University Hospital Complex, Lyon, FR. We asked Gilles Salles to summarize the practice-changing abstracts in indolent lymphoma presented at ASH 2019.
Gilles Salles talks about important emerging therapies that are being explored in patients with indolent lymphomas such as bispecific antibodies. He also discusses the results of the AUGMENT study and explains the patient outcomes. Gilles Salles also talks about the novel agent, tazemetostat, and discusses the patient responses.
Practice-changing abstracts in indolent lymphoma presented at ASH 2019